<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1038">
  <stage>Registered</stage>
  <submitdate>15/06/2006</submitdate>
  <approvaldate>20/06/2006</approvaldate>
  <actrnumber>ACTRN12606000248561</actrnumber>
  <trial_identification>
    <studytitle>A phase 1 randomised double blind, placebo-controlled, single dose, dose escalation study of KB002, a chimeric monoclonal antibody which binds to granulocyte macrophage-colony stimulating factor (GM-CSF), in patients with rheumatoid arthritis</studytitle>
    <scientifictitle>A phase 1 randomised double blind, placebo-controlled, single dose, dose escalation study of the safety and tolerability profile of KB002, a chimeric monoclonal antibody which binds to granulocyte macrophage-colony stimulating factor (GM-CSF), in patients with rheumatoid arthritis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Rheumatoid arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single dose of KB002 administered intravenously over one hour to patients with rheumatiod arthritis.  </interventions>
    <comparator>A single dose of placebo (0.9% sodium chloride for infection) administered intravenously over one hour to patients with rheumatiod arthritis.  </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The safety profile of KB002 in patients with rheumatoid arthritis</outcome>
      <timepoint>At day 29</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The tolerability profile of KB002 in patients with rheumatoid arthritis</outcome>
      <timepoint>At day 29</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy and pharmacokinetics of KB002.</outcome>
      <timepoint>At Day 29.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Active rheumatoid arthritisCurrently receiving treatment with methotrexateStable doses of disease modifying anti-rheumatic drugs (DMARDs) for at least 8 weeksSwollen joint count of at least 6 (using 66 joint count)Tender joint count of at least 6 (using 68 joint count)Two out of three of the following:Erythrocyte sedimentation rate (ESR) greater than or equal to 20 mm/hrC-reactive protein (CRP) greater than or equal to 15 mg/dLEarly morning stiffness of greater than or equal to 45 minutes.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Concurrent treatment with approved or investigational biological rheumatoid arthritis therapiesWhite blood cell (WBC) &lt; 3.5 x 10^9/LAny major surgical operation or infrction within the last 8 weeks History of solid or haematological malignancy within the past 10 yearsFemales who are pregnant or breastfeedingMales or females unable to practice effective methods of birth control for 3 months after the infusion of study drugCurrent or past history of severe cardiac diseaseCurrent respiratory disease or a past history of chronic respiratory diseasePartial pressure of oxygen in arterial blood (PaO2) &lt; 95% on room airCurrent smokers or a greater than or equal to 10 pack year history for ex-smokersImmune deficiency, chronic infections or chronic imflammatory conditiond other than rheumatoid arthritisDemylinating neurological disordersFelty's syndrome or myasthenia gravisAny other illness Current or past treatmant with granulocyte macrophage-colony stimulating factor (GM-CSF) or granulocyte-colony stimulating factor (G-CSF)Previous treatment with an investigational agent within the last 90 daysVaccination within the last 30 days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone/fax/computer</concealment>
    <sequence>Computerised random number generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>7/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KaloBios Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress>3427 Hillview Avenue, Suite 200
Palo Alto, CA 94304</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>KaloBios Pharmaceuticals, Inc.</fundingname>
      <fundingaddress>3427 Hillview Avenue, Suite 200
Palo Alto, CA 94304</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Kendle R&amp;D Pty Limited</sponsorname>
      <sponsoraddress>156 - 158 Drummond Street
Oakleigh   Victoria   3166
Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to investigate the safety and the pharmacokinetics of KB002 in patients with rheumatoid arthritis.  Patients will be randomly assigned 3:1 to KB002 or placebo.  The study is double-blinded, with only the pharmacist unblinded.  The investigator, study coordinator, patient, clinical research orgination (CRO) and sponsor are blinded to the treatment assignment.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Repatriation General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/05/2006</ethicapprovaldate>
      <hrec>09/06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tillman Pearce, MD</name>
      <address>3427 Hillview Avenue, Suite 200
Palo Alto  CA  94304</address>
      <phone>+1 650 8431897</phone>
      <fax>+1 650 8431896</fax>
      <email>slight@kalobios.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Howard</name>
      <address>3427 Hillview Avenue, Suite 200
Palo Alto, CA  94304</address>
      <phone>+1 650 8431897</phone>
      <fax>+1 650 8431896</fax>
      <email>choward@kalobios.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>